IMF Videos Search Content For Healthcare Professional (124) Healthcare Provider (124) Care Partner (77) Patient (76) Series - Any - ASCO/EHA (50) ASH (60) Ask Dr. Durie (16) Black Swan Research Initiative (5) Community Workshops (4) Emerging Therapies (6) Facebook Live (10) Health Equity (2) IMWG (3) Inspirational (3) Living Well with Myeloma (4) Myeloma in a Minute (1) Myeloma Made Simple (3) Patient & Family Webinar (4) Q&A (7) Recent News and Developments (4) Treatments (1) Trending Searches in Myeloma (1) Topics Clinical Trials (186) Financial Considerations (15) Frontline Therapy (84) Health Equity (34) Inspirational Stories (23) Insurance (6) Lab & Imaging Tests (72) Lifestyle (47) Mental & Emotional Health (29) Myeloma 101 (59) Myeloma in the News (8) Public Policy & Advocacy (17) Q&A's (43) Recorded Seminars & Workshops (15) Recorded Webinars (24) Relapse/Refractory Myeloma (138) Research Updates (194) Symptom Management (115) Myeloma Stage Early Relapse (1–3 Lines of Therapy) (67) High-Risk Myeloma (44) High-risk Smoldering Myeloma (36) Late Relapse (4–6 Lines of Therapy) (83) MGUS (37) Newly Diagnosed (Pre-Treatment or First Treatment) (66) Smoldering Myeloma (52) Types of Therapy Immunomodulatory drugs (IMiDs) (60) Immunotherapies (CAR T; BiTE, etc.) (95) Monoclonal antibodies (50) Proteasome inhibitors (45) Stem cell transplant (42) Steroids (41) Supportive Care (36) Year Published 2026 (18) 2025 (38) 2024 (58) 2023 (39) 2022 (10) 2021 (7) 2020 (1) 2019 (9) 2018 (2) 2017 (1) 2016 (3) Trusted Voices Dr. Joseph Mikhael (36) Dr. Brian GM Durie (15) Dr. María-Victoria Mateos (6) Beth Faiman, PhD, MSN, APN-BC, AOCN®, BMTCN®, FAAN, FAPO (5) Dr. Saad Usmani (3) Dr. Sigurður Kristinsson (3) Dr. Shaji Kumar (2) Dr. Urvi A. Shah (2) Dr. Sagar Lonial (1) Sort Newest firstOldest firstA -> ZZ -> ARelevance Myeloma Made Simple: Bispecific Antibody Targets Made Simple | Myeloma Targeting with Bispecifics June 6, 2024 Myeloma Made Simple Myeloma Made Simple: Xpovio (Selinexor) Made Simple | Selinexor for Multiple Myeloma Treatment May 15, 2024 Myeloma Made Simple What should be done if a patient relapses while in a clinical trial? April 19, 2024 Ask Dr. Durie How valuable is minimal residual disease testing for myeloma patients? April 11, 2024 Ask Dr. Durie Ask Me Anything Replay: Insights from Dr. Urvi A. Shah, Memorial Sloan Kettering April 4, 2024 Facebook Live Ask Me Anything Replay: Insights from IMF NLB Member Beth Faiman March 27, 2024 Facebook Live Ask Me Anything Replay: Dr. Mikhael and Dr. Kaur Discuss Myeloma Live March 27, 2024 Facebook Live IMF Patient and Family Seminar 2024 — Boca Raton, FL March 15, 2024 Patient & Family Webinar What are early insights from iStopMM regarding preventing myeloma progression? March 14, 2024 Ask Dr. Durie Real World Outcomes with Idecabtagene Vicleucel (Ide-Cel) CAR-T Cell Therapy for Relapsed/Refractory Multiple Myeloma February 22, 2024 ASH Early Safety Results of P-BCMA-ALLO1, a Fully Allogeneic Chimeric Antigen Receptor T-Cell (CAR-T), in Patients with Relapsed / Refractory Multiple Myeloma (RRMM) February 15, 2024 ASH Treatment Outcomes and Prognostic Factors with Lenalidomide, Bortezomib, and Dexamethasone (RVd) Alone Versus Rvd Plus Autologous Stem Cell Transplantation (ASCT) in African American (AA) Patients with Newly Diagnosed Myeloma in the Determination Trial February 15, 2024 ASH Load More
